Developing novel medicines that modulate metabolic pathways in immune cells to treat disease
Rheos Medicines is a biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease. The company’s approach targets the underlying cellular metabolism of immune cells to redirect the fate and function of specific cell types to treat immune-mediated disease. By simultaneously identifying new drug targets and characterizing biomarkers of disease the company is bringing precision to the treatment of immune-mediated diseases.
Year Invested: 2018
Location: Cambridge, MA